| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $165.8M+521.6% | $26.7M-51.9% | $55.5M+51.6% | $36.6M+38.9% | $26.4M-9.4% | $29.1M+247.6% | $8.4M |
| Short-term investments – available for sale | $539.9M-38.4% | $875.9M+185.7% | $306.6M+157.9% | $118.9M-32.4% | $175.7M-19.9% | $219.3M-18.0% | $267.3M |
| Prepaid clinical trial and preclinical study costs | $8.1M+131.7% | $3.5M+32.5% | $2.6M-67.8% | $8.1M+4.3% | $7.8M+7.3% | $7.3M-2.4% | $7.5M |
| Prepaid expenses and other current assets | $1.8M+60.1% | $1.1M-55.3% | $2.5M-26.1% | $3.4M+451.1% | $619K+40.0% | $442K+9.1% | $405K |
| Total current assets | $715.6M-21.1% | $907.2M+147.0% | $367.2M+119.8% | $167.0M-20.7% | $210.5M-17.8% | $256.1M-9.7% | $283.5M |
| Right-of-use assets | $85K-91.5% | $1.0M-10.9% | $1.1M-20.6% | $1.4M+5572.0% | $25K-92.2% | $321K-46.3% | $598K |
| Deferred financing costs | $0-100.0% | $56K-47.2% | $106K+178.9% | $38K-50.0% | $76K | — | — |
| Deposits | $46K+0.0% | $46K+39.4% | $33K+0.0% | $33K+0.0% | $33K+13.8% | $29K+0.0% | $29K |
| Total assets | $715.7M-21.2% | $908.3M+146.5% | $368.5M+118.7% | $168.5M-20.0% | $210.7M-17.9% | $256.5M-9.8% | $284.3M |
| Accounts payable | $53.3M+442.7% | $9.8M+30.6% | $7.5M-11.9% | $8.5M+490.7% | $1.4M-63.8% | $4.0M+64.0% | $2.4M |
| Other accrued liabilities | $23.3M+36.0% | $17.1M+51.4% | $11.3M-13.8% | $13.1M+79.5% | $7.3M-6.5% | $7.8M+93.2% | $4.0M |
| Lease liability, current | $137K-72.0% | $489K+50.9% | $324K+6.6% | $304K+948.3% | $29K-91.2% | $330K+9.3% | $302K |
| Total current liabilities | $76.7M+179.7% | $27.4M+43.3% | $19.1M-12.8% | $21.9M+150.0% | $8.8M-27.6% | $12.1M+79.0% | $6.8M |
| Lease liability, net of current portion | $0-100.0% | $630K-32.7% | $936K-25.7% | $1.3M | — | — | $360K |
| Total long-term liabilities | $0-100.0% | $630K-32.7% | $936K-25.7% | $1.3M | — | — | $360K |
| Total liabilities | $76.7M+173.4% | $28.0M+39.7% | $20.1M-13.5% | $23.2M+164.4% | $8.8M-27.8% | $12.2M+70.4% | $7.1M |
| Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2025 and December 31, 2024; 114,793,067 shares issued and outstanding at December 31, 2025 and 111,573,519 shares issued and outstanding at December 31, 2024 | $1K+0.0% | $1K+0.0% | $1K+0.0% | $1K+0.0% | $1K+0.0% | $1K+0.0% | $1K |
| Treasury stock at cost, no shares at December 31, 2025 and December 31, 2024 | $0 | $0+100.0% | -$6.8M+0.0% | -$6.8M | — | — | — |
| Additional paid-in capital | $1.49B+8.6% | $1.37B+86.6% | $733.5M+64.7% | $445.3M+4.6% | $425.6M+3.2% | $412.6M+1.7% | $405.8M |
| Accumulated deficit | -$847.5M-73.7% | -$487.9M-29.1% | -$377.9M-29.4% | -$292.0M-30.9% | -$223.2M-32.7% | -$168.2M-30.7% | -$128.7M |
| Accumulated other comprehensive loss | $378K+148.0% | -$788K-102.6% | -$389K+64.7% | -$1.1M-100.7% | -$549K-916.7% | -$54K-550.0% | $12K |
| Total stockholders’ equity | $639.1M-27.4% | $880.3M+152.6% | $348.4M+139.8% | $145.3M-28.0% | $201.9M-17.4% | $244.3M-11.8% | $277.1M |
| Total liabilities and stockholders’ equity | $715.7M-21.2% | $908.3M+146.5% | $368.5M+118.7% | $168.5M-20.0% | $210.7M-17.9% | $256.5M-9.8% | $284.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.